Live Quote · NASDAQIMTXHealthcare· Biotechnology

Immatics N.V.

$9.95 1.02%(+$0.10)
TickerSpark Score
44/100
Weak
55
Valuation
40
Profitability
10
Growth
84
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMTX research report →

52-Week Range67% of range
Low
$5.05
Current
$9.95
High
$12.41
Company Overviewwww.immatics.com

About the company

Immatics N. V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States.

CEO
Harpreet Singh
IPO
2018
Employees
554
HQ
Tübingen, DE

Price Chart

+78.00% · this period
$11.87$8.48$5.09Jul 02Dec 31Jul 02
Valuation
Market Cap
$1.33B
P/E
-5.09
P/S
31.27
P/B
2.57
EV/EBITDA
-4.35
Div Yield
0.00%
Profitability
Gross Margin
100.00%
Op Margin
-570.30%
Net Margin
-574.86%
ROE
-45.27%
ROIC
-43.12%
Growth & Income
Revenue
$48.27M · -69.03%
Net Income
$-196,447,000 · -1390.89%
EPS
$-1.54 · -1200.00%
Op Income
$-182,016,000
FCF YoY
-0.83%
Performance & Tape
52W High
$12.41
52W Low
$5.05
50D MA
$10.51
200D MA
$9.98
Beta
1.32
Avg Volume
464.35K

Get TickerSpark's AI analysis on IMTX

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jun 16, 26Stone Adam Leoother48,000
Jun 16, 26REICIN ALISEother48,000
Jun 16, 26ATIEH MICHAEL Gother48,000
Jun 16, 26Carter Paul Rutherfordother48,000
Jun 16, 26Forster Eliotother48,000
Jun 16, 26Chambre Peter Alanother48,000
Jun 16, 26Mason Heather Lother48,000
Jun 16, 26PERCEPTIVE ADVISORS LLCother48,000
Jun 16, 26Hothum Mathiasother48,000
Mar 18, 26Reinhardt Carsten Alexander Johannesother0
Coverage · IMTX

Our IMTX coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on IMTX yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate IMTX report →
Internal Compare

Similar companies

Peers in the same neighborhood.